TY - JOUR
T1 - Oncolytic Myxoma virus infects and damages the tegument of the human parasitic flatworm Schistosoma mansoni
AU - Rahman, Masmudur M.
AU - McFadden, Grant
AU - Ruthel, Gordon
AU - Herbert, De'Broski B.R.
AU - Freedman, Bruce D.
AU - Greenberg, Robert M.
AU - Bais, Swarna
N1 - Funding Information:
This work was funded by National Institute of Health ( https://www.nih.gov/ ) grants NIH R01-AI123173 , to RMG and NIH R21AI151334-01A1 to SB. G.M. and M.M.R's research is supported by an ASU start -up grant and NIH grant RO1-Al080607. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2022
PY - 2022/8
Y1 - 2022/8
N2 - Schistosomiasis is a devastating disease caused by parasitic flatworms of the genus Schistosoma. Praziquantel (PZQ), the current treatment of choice, is ineffective against immature worms and cannot prevent reinfection. The continued reliance on a single drug for treatment increases the risk of the development of PZQ-resistant parasites. Reports of PZQ insusceptibility lends urgency to the need for new therapeutics. Here, we report that Myxoma virus (MYXV), an oncolytic pox virus which is non-pathogenic in all mammals except leporids, infects and replicates in S. mansoni schistosomula, juveniles, and adult male and female worms. MYXV infection results in the shredding of the tegument and reduced egg production in vitro, identifying MYXV as the first viral pathogen of schistosomes. MYXV is currently in preclinical studies to manage multiple human cancers, supporting its use in human therapeutics. Our findings raise the exciting possibility that MYXV virus represents a novel and safe class of potential anthelmintic therapeutics.
AB - Schistosomiasis is a devastating disease caused by parasitic flatworms of the genus Schistosoma. Praziquantel (PZQ), the current treatment of choice, is ineffective against immature worms and cannot prevent reinfection. The continued reliance on a single drug for treatment increases the risk of the development of PZQ-resistant parasites. Reports of PZQ insusceptibility lends urgency to the need for new therapeutics. Here, we report that Myxoma virus (MYXV), an oncolytic pox virus which is non-pathogenic in all mammals except leporids, infects and replicates in S. mansoni schistosomula, juveniles, and adult male and female worms. MYXV infection results in the shredding of the tegument and reduced egg production in vitro, identifying MYXV as the first viral pathogen of schistosomes. MYXV is currently in preclinical studies to manage multiple human cancers, supporting its use in human therapeutics. Our findings raise the exciting possibility that MYXV virus represents a novel and safe class of potential anthelmintic therapeutics.
KW - Myxoma virus
KW - Schistosome
KW - Tegument
UR - http://www.scopus.com/inward/record.url?scp=85132379582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132379582&partnerID=8YFLogxK
U2 - 10.1016/j.exppara.2022.108263
DO - 10.1016/j.exppara.2022.108263
M3 - Article
C2 - 35598646
AN - SCOPUS:85132379582
SN - 0014-4894
VL - 239
JO - Experimental Parasitology
JF - Experimental Parasitology
M1 - 108263
ER -